5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
BUY | BUY | SELL | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 1.61▲ | 1.57▲ | 1.56▲ | 1.69▼ | 1.71▼ |
MA10 | 1.59▲ | 1.55▲ | 1.62▲ | 1.70▼ | 1.62▲ |
MA20 | 1.57▲ | 1.62▲ | 1.67▼ | 1.72▼ | 1.64▼ |
MA50 | 1.55▲ | 1.68▼ | 1.66▼ | 1.58▲ | 6.50▼ |
MA100 | 1.59▲ | 1.66▼ | 1.71▼ | 1.68▼ | 7.23▼ |
MA200 | 1.66▼ | 1.70▼ | 1.68▼ | 5.39▼ | 18.47▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.006▲ | 0.004▲ | -0.015▼ | -0.012▼ | 0.364▲ |
RSI | 73.414▲ | 50.556▲ | 48.376▼ | 48.251▼ | 33.222▼ |
STOCH | 98.333▲ | 76.198 | 42.998 | 37.556 | 57.319 |
WILL %R | 0.000▲ | -39.130 | -42.857 | -52.101 | -48.837 |
CCI | 190.323▲ | 77.778 | -22.755 | -154.373▼ | 15.376 |
Thursday, January 23, 2025 08:49 AM
ALX Oncology (NASDAQ:ALXO) stock fell 16% Thursday after the company reported updated data from a Phase 2 study called ASPEN-06 for its drug candidate evorpacept. ALX said the data showed evorpacept ...
|
Thursday, January 23, 2025 06:04 AM
SOUTH SAN FRANCISCO - ALX Oncology Holdings Inc. (NASDAQ:ALXO), a clinical-stage biotechnology company with a market capitalization of approximately $95 million, reported positive outcomes from its ...
|
Thursday, January 23, 2025 05:10 AM
ALX Oncology (ALXO) announced positive updated data from the ASPEN-06 Phase 2 clinical trial demonstrating that the company’s investigational ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
23/01/25 | 1.45 | 1.63 | 1.345 | 1.63 | 6,378,260 |
22/01/25 | 1.76 | 1.87 | 1.66 | 1.80 | 1,440,004 |
21/01/25 | 1.80 | 1.80 | 1.6301 | 1.65 | 1,605,290 |
17/01/25 | 1.63 | 1.77 | 1.625 | 1.74 | 579,746 |
16/01/25 | 1.64 | 1.6498 | 1.58 | 1.63 | 294,465 |
15/01/25 | 1.61 | 1.69 | 1.56 | 1.63 | 449,500 |
14/01/25 | 1.69 | 1.766 | 1.58 | 1.59 | 546,811 |
13/01/25 | 1.85 | 1.8505 | 1.63 | 1.69 | 818,855 |
10/01/25 | 1.81 | 1.865 | 1.71 | 1.77 | 1,078,511 |
08/01/25 | 1.85 | 1.94 | 1.7707 | 1.85 | 994,185 |
|
|
||||
|
|
||||
|
|